- Home
- IBIO vs LIXT Comparison
IBIO vs LIXT Comparison
Compare IBIO & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- LIXT
- Stock Information
- Founded
- IBIO 2008
- LIXT 2005
- Country
- IBIO United States
- LIXT United States
- Employees
- IBIO N/A
- LIXT N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- LIXT Health Care
- Exchange
- IBIO Nasdaq
- LIXT Nasdaq
- Market Cap
- IBIO 11.9M
- LIXT 12.4M
- IPO Year
- IBIO N/A
- LIXT N/A
- Fundamental
- Price
- IBIO $0.79
- LIXT $3.41
- Analyst Decision
- IBIO Strong Buy
- LIXT
- Analyst Count
- IBIO 2
- LIXT 0
- Target Price
- IBIO $5.50
- LIXT N/A
- AVG Volume (30 Days)
- IBIO 723.2K
- LIXT 136.6K
- Earning Date
- IBIO 09-19-2025
- LIXT 08-07-2025
- Dividend Yield
- IBIO N/A
- LIXT N/A
- EPS Growth
- IBIO N/A
- LIXT N/A
- EPS
- IBIO N/A
- LIXT N/A
- Revenue
- IBIO $375,000.00
- LIXT N/A
- Revenue This Year
- IBIO $81.33
- LIXT N/A
- Revenue Next Year
- IBIO N/A
- LIXT N/A
- P/E Ratio
- IBIO N/A
- LIXT N/A
- Revenue Growth
- IBIO 650.00
- LIXT N/A
- 52 Week Low
- IBIO $0.56
- LIXT $0.64
- 52 Week High
- IBIO $6.89
- LIXT $5.14
- Technical
- Relative Strength Index (RSI)
- IBIO 60.85
- LIXT 44.33
- Support Level
- IBIO $0.67
- LIXT $3.13
- Resistance Level
- IBIO $0.81
- LIXT $4.04
- Average True Range (ATR)
- IBIO 0.07
- LIXT 0.57
- MACD
- IBIO 0.02
- LIXT -0.22
- Stochastic Oscillator
- IBIO 89.29
- LIXT 16.66
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.